UNITED STATES COURT OF APPEALS 

FOR THE FIRST CIRCUIT 

Docket No. 07-1945 

IMS HEALTH INCORPORATED, a Delaware Corporation; 

and VERISPAN, LLC, a Delaware Limited Liability Company 

v. 

KELLY A. AYOTTE, Attorney General 

of the State of New Hampshire 

JOINT STIPULATION REGARDING THE RECORD

 Plaintiffs, IMS Health Incorporated and Verispan LLC and New Hampshire 

Attorney General jointly stipulate that the record in this case consists of the 

testimony of the witnesses offered at trial and the following exhibits: 

Joint Trial Exhibits

 1. Legislative History of House Bill 1346. 

Plaintiff’s Exhibits

Trial 

Exhibit No. Exhibit Description

 1. 11/09/06 Deposition of John P. Glaser with Exhibit 

 2. 11/09/06 Deposition of Andrew J. Cole with Exhibits 

3. 11/13/06 Deposition of Göran Albert Tortensson Ando, M.D. 

with Exhibit 

 4. 11/20/06 Deposition of Jody Fisher with Exhibits 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 1 of 9
2 

 5. 11/20/06 Deposition of Hossam Sadek with Exhibits 

 6. 11/21/06 Deposition of August J. Dobish with Exhibits 

 7. 12/07/06 Deposition of Thomas Wharton, M.D. 

 8. 07/20/06 Declaration of Thomas P. Wharton Jr., M.D., F.A.C.C 

 with Exhibit, which consists of Curriculum Vitae. 

 9. 07/27/06 Declaration of Robert J. Hunkler 

 10. 07/27/06 Declaration of Jody Fisher 

 11. 07/27/06 Declaration of Hossam Sadek 

 12. 07/26/06 Declaration of Göran Ando 

 13. 07/27/06 Declaration of Randolph B. Frankel 

 14. 07/27/06 Declaration of James Mahon 

 15. 07/2706 Declaration of Jeremy Eggleton 

 16. 08/30/06 Declaration of August Dobish 

 17. 10/16/06 Declaration of Dr. John Glaser 

 18. 10/16/06 Declaration of Dr. Andrew Cole, M.D., F.R.C.P. (C.) 

 with Exhibit which consists of Curriculum Vitae.

 19. Okie, Susan, AMA Criticized for Letting Drug Firms Pay for 

Ethics Campaign, The Washington Post (Aug. 30 2001) 

(Exhibit 2 to Dr. Avorn’s Deposition). 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 2 of 9
3 

 20. Mitzik, Natalie & Jacobson, Robert, Are Physicians “Easy 

Marks”? Quantifying the Effects of Detailing and Sampling on 

New Prescriptions, Management Science, Vol. 50, No. 12 (Dec. 

2004) (Exhibit 3 to Dr. Avorn’s Deposition). 

 21. “Show Me the Evidence,” a project of the Canadian Academic 

Detailing Collaboration and Drug Policy Futures (Exhibit 4 to 

Dr. Avorn’s Deposition). 

 22. Avorn M.D., Jerry Powerful Medicines, The Benefits, Risks and 

Costs of Prescription Drugs, (Exhibit 5 to Dr. Avorn’s 

Deposition). 

 23. National Prescribing Service Limited, 

http://www.nps.org.au.site.php?page=2&content=/resources%2

Fcontent%2Fnps_whowe... (Exhibit 6 to Dr. Avorn’s 

Deposition). 

 

 24. The Health Report, Drug Regulation and Drug Safety 

http://www.abc.go.au./rn/healthreport/stories/2006/1657545.htm 

(Exhibit 7 to Dr. Avorn’s Deposition). 

 25. Market Watch Article: Extensions of Intellectual Property 

Rights and Delayed Adoption of Generic Drugs: Effects on 

Medicaid Spending by Aaron S. Kesselheim, Michael A. 

Fischer and Jerry Avorn, Health Affairs, Vol. 25, No. 6 (De. 

2006) (Exhibit 1 to Kesselheim’s Deposition). 

26. Prozac® Fluoxetine Capsules, USP (PV 5321 DPP) (Exhibit 1 

to Ahari’s Deposition). 

27. Zyprexa® ZYSDIS® (PV 5195 AMP) (Exhibit 2 to Ahari’s 

Deposition). 

 28. The Red Book (Exhibit 3 to Ahari’s Deposition). 

 29. IMS Health Solutions Overview 

 http://wwwimshealth.com/ims/portal/front/ 

indexC/o,02773,6599_43089758_0,00.html (Exhibit 2 to 

Sadek’s Deposition). 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 3 of 9
4 

30. Safety Information Alerts/ FDA Public Health Advisory (July 

19, 2006) 

http://fda.ov/medwathc/safety/2006/safety06.htm (Exhibit 3 to 

Sadek’s Deposition). 

 31. Supporting Documentation to Hossam Sadek’s Declaration 

(Exhibit 4 to Sadek’s Deposition). 

32. Articles Reviewed by Dr. Andrew Cole (Exhibit 2 to Cole’s 

Deposition). 

51. Details for large brands with expiry in 2005 or 2006 (chart used 

in Hossam Sadek’s Deposition). 

52. Generic Erosion of large brands with expiry in 2005 and 2006 

[by week] (chart used in Hossam Sadek’s Deposition). 

53. Generic Erosion of large brands with expiry in 2005 and 2006 

[by month] (chart used in Hossam Sadek’s Deposition). 

54. In New Hampshire for the same products, Generic erosion is 

similar to national rates (chart used in Hossam Sadek’s 

Deposition). 

56. Crestor® Powerpoint Presentation by Jeanne Bruno-Joyce, 

PharmD. 

61. Evolution of Clinical Practice Guidelines, Evidence Supporting 

Standard Use of Medicines. 

63. Shahram Ahari’s Manager Exit Report from Eli Lilly & Co. 

65. Research Request to IMS. 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 4 of 9
5 

State’s Exhibits

Trial 

Exhibit No. Exhibit Description 

A(1) Declaration Dr. Jerry Avorn and Dr. Aaron Kesselheim. 

A(2) Okie S. AMA Criticized For Letting Drug Firms Pay For 

Ethics Campaign. Wash Post. Aug 30, 2001 

A(3) Dana J, Loewenstein G. A Social Science Perspective On Gifts 

To Physicians From Industry. JAMA 2003;290:252-255. 

A(4) Peay MY & Peay ER. The Role Of Commercial Sources In 

Adoption Of A New Drug. Soc Sci Med 1988;26(12):1183-9 

A(5) Berndt ER, Bui L, Reiley DR, Urban GL. Information, 

Marketing, And Pricing In The US Antiulcer Drug Market. 

Amer Econ Rev 100 1995;85:100-5 

A(6) Wazana A. Physicians And The Pharmaceutical Industry: Is A 

GiftEever Just A Gift?JAMA 2000;283:373-80 

A(7) Peay MY & Peay ER. Innovation In High Risk Drug Therapy. 

Soc Sci Med 1994; 39(1):39-52 

A(8) Chren M-M & Landefeld CS. Physicians’ Behavior And Their 

Interactions With Drug Companies: Aa Controlled Study Of 

Physicians Who Requested Additions To A Hospital Drug 

Formulary. JAMA 1994; 271:684-9 

A(9) Manchanda P, Honka E. The Effects And Role Of Direct-ToPhysician Marketing In The Pharmaceutical Industry: An 

Integrative Review. Yale J. Health Policy Law & Ethics 2005; 

5:785-8 

A(10) Avorn J, Chen M, Hartley R. Scientific Versus Commercial 

Sources Of Influence On The Prescribing Behavior Of

Physicians. Am J Med. Jul 1982; 73(1):4-8 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 5 of 9
6 

A(11) Blumenthal D. Doctors And Drug Companies. NEJM 2004; 

351:1885-90. 

A(12) Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas 

SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Smelser N. 

Health Industry Practices That Create Conflicts Of Interest: A 

Policy Proposal For Academic Medical Centers. JAMA 2006; 

295:429-33 

A(13) Windmeijer F, de Laat E, Douven R, Mot E. Pharmaceutical 

Promotion And GP Prescription Behavior. Health Econ 2006; 

15:5-18 

A(14) Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, 

Lessler DS. A Physician Survey On Effect Of Drug Sample 

Availability On Physicians’ Behavior. JGIM 2000;15:478-83. 

A(15) Boltri JM, Gordon ER, Vogel RL. Effect Of Antihypertensive 

Samples On PhysicianPrescribing Patterns. Family Medicine 

Nov-Dec 2002; 34(10):729-31. 

A(16) Cardarelli R, Licciardone JC, Taylor LG. A Cross-Sectional 

Evidence-Based Review Of Pharmaceutical Promotional

Marketing Brochures And Their Underlying Studies: Is What 

They Tell Us Important And True? BMC Fam Pract. 2006; 

7:13. 

A(17) Fischer MA, Avorn J. Economic Implications Of EvidenceBased Prescribing For Hypertension: Can Better Care Cost 

Less? JAMA 2004; 291:1850-6. 

A(18) Kesselheim AS, Fischer MA, Avorn J. The Rise And Fall Of 

Natrecor For Congestive Heart Failure: Implications For Drug 

Policy. Health Affairs 2006; 25(4):1095-102 

A(19) Ziegler MG, Lew P, Singer BC. The Accuracy Of Drug 

Information From Pharmaceutical Sales Representatives. 

JAMA 1995; 273:1296-8. 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 6 of 9
7 

A(20) Avorn J & Soumerai SB. Improving Drug-Therapy Decisions 

Through Educational Outreach. A Randomized Controlled 

Trial Of Academically Based “Detailing” N Engl J Med 1983; 

308:1457-63 

A(21) Avorn J, Soumerai SB, Everitt DE, Ross-Degnan D, Beers MH, 

Sherman D, Salem-Schatz SR, Fields D. A Randomized Trial 

Of A Program To Reduce The Use Of Psychoactive Drugs In 

Nursing Homes. N Engl J Med 1992; 327:168-73. 

 

 B. CV Dr. Jerry Avorn. 

 C. 11/27/06 deposition transcript Dr. Jerry Avorn. 

 D. Declared portions of Dr. Jerry Avorn’s deposition. 

 E. Avorn deposition Exhibit 4, Show Me The Evidence, 2006. 

 F. CV Dr. Aaron S. Kesselheim 

 G. 11/27/06 deposition transcript Dr. Aaron S. Kesselheim. 

 H. Declaration Dr. Gary A. Sobelson. 

 I. CV Dr. Gary A. Sobelson. 

 J. 11/16/06 Deposition transcript Dr. Gary A. Sobelson. 

 K. Declared Portions of Dr. Gary A. Sobelson’s Deposition. 

 L. Declaration Dr. Marc Sadowsky. 

 M. CV Dr. Marc Sadowsky. 

 N. 12/21/06 Deposition transcript Dr. Marc Sadowsky. 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 7 of 9
8 

 O. Declared Portions of Dr. Marc Sadowsky’s Deposition. 

 P. Declaration Shahram Ahari. 

 Q. CV Shahram Ahari. 

 

 R. 11/28/06 Deposition transcript Dr. Shahram Ahari. 

 S. Declared portions of Shahram Ahari. 

 T. No exhibit 

 U. Line by line of breakdown of legislation (RSA 318:47-f). 

 V. IMS Intelligence Applied. 

W. May 5, 2005 Memorandum to Democratic Members of the 

Government Reform Committee. 

Respectfully submitted, 

THE STATE OF NEW HAMPSHIRE, 

by its attorneys, 

Kelly A. Ayotte 

Attorney General 

Date: ____________ _________________________________ 

Richard W. Head 

Associate Attorney General 

N.H. Bar No. 7900 

First Circuit Court No. 62437 

33 Capitol Street 

Concord, New Hampshire 03301-6397 

(603) 271-1248 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 8 of 9
9 

Certificate of Service

July 3, 2007 

 I hereby certify that a copy of the foregoing was mailed this day, by first 

class mail to: 

James Bassett, Esquire 

Jeffrey C. Spear, Esquire 

Orr & Reno, PA 

One Eagle Square 

P.O. Box 3550 

Concord, NH 03302-3550 

Mark A. Ash, Esquire 

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP 

2500 Wachovia Capitol Center 

Raleigh, NC 27601 

Thomas R. Julin, Esquire 

Patricia Acosta, Esquire 

Hunton & Williams, LLP 

111 Brickell Avenue, Suite 2500 

Miami, FL 33131 

_________________________________ 

Richard W. Head 

Associate Attorney General 

N.H. Bar No. 7900 

First Circuit Court No. 62437 

203191.doc 

Case 1:06-cv-00280-PB Document 143-2 Filed 07/18/2007 Page 9 of 9